#Ireland #Dublin #Serialization #AssureTrace #Graham Clark

AssureTrace Appoints Graham Clark as Chief Business and Revenue Officer

On November 10, 2026, AssureTrace, the Irish company pioneering second-generation serialization management for the pharmaceutical industry, named Graham Clark as its new Chief Business and Revenue Officer, as well as a member of the board of directors. This strategic appointment underscores AssureTrace's commitment to enhancing its operational efficacy and expanding its footprint within a competitive market.

Graham Clark is a recognized leader in serialization and traceability, with a background that includes co-founding TraceLink. His extensive expertise encompasses a wealth of implementing compliance measures, notably the EU's Falsified Medicines Directive (FMD) and the U.S. Drug Supply Chain Security Act (DSCSA). With over 23 years of international experience, his role at AssureTrace is pivotal as the company aims to bolster its regulatory compliance offerings and technological integration in the pharmaceutical sector.

Clark emphasized the evolution of serialization practices from mere implementation to maintaining reliable compliance on a daily basis. He noted, "The first generation of serialization focused on executing systems and meeting regulatory deadlines. Today, businesses face the challenge of ensuring compliance consistently across the markets they operate in."

At AssureTrace, Clark will leverage his expertise to navigate the complexities of serialization and compliance in various markets. He articulated that keeping serialization expertise in-house can be challenging for companies. AssureTrace's approach combines a structured operational model with proven technological solutions and a network of trusted managed service providers, all of which collaboratively work to transform regulatory requirements into dependable everyday operations for pharmaceutical companies.

He further explained, "There’s been a shift from on-premise systems to cloud-based solutions and then to managed services. The motivations for adopting managed services have evolved from purely cost considerations to factors like shared expertise, flexibility, and agility. When specialists handle routine tasks, the emergence of new markets, partners, or standards can simply adjust services rather than warranting the initiation of new in-house projects."

The firm’s second-generation serialization, delivered as a managed service, is expected to allow the industry to adapt to new technologies as quickly as they emerge. AssureTrace's service-oriented model focuses on operational efficiency, linking local compliance operations executed by qualified service providers under a unified AssureTrace standard with SoftGroup technology developed in Europe.

The clients retain regulatory accountability while enjoying enhanced supervisory capabilities. Impressively, the SoftGroup platform has replaced first-generation systems in 40 companies, showcasing a robust transition to advanced serialization technologies.

Venelin Dimitrov, co-founder and CEO of AssureTrace, expressed his enthusiasm about Clark's appointment, stating, "Graham's international experience and understanding of the pharmaceutical serialization landscape will be crucial as we expand AssureTrace and our partner network through Europe and North America. For more than two decades, SoftGroup has developed serialization technology that 167 pharmaceutical clients in 43 markets rely on, boasting a 98% retention rate. AssureTrace builds on this foundation to deliver continuous operational support for regulatory compliance through a service-focused model."

As AssureTrace continues to define its role in the pharmaceutical serialization landscape, Graham Clark's appointment heralds a new chapter for the company as it strives to address the ongoing demands for regulatory compliance while fostering innovation and operational excellence.

For more information about AssureTrace and its commitment to serialization and compliance solutions, visit AssureTrace's Official Website.